David Steensma, MD FACP is Chief Medical Officer of Ajax Therapeutics in Cambridge,
Massachusetts. Prior to becoming the Global Head of Hematology for Novartis from
2020-2023, he served for 18 years as a faculty member at Mayo Clinic and Dana-
Farber Cancer Institute (DFCI)/Harvard Medical School (HMS), focused on myelodysplastic
syndromes (MDS) and clonal hematopoiesis, and was principal investigator or sub-
investigator on many multi-center clinical trials for MDS and other myeloid neoplasms.
He is a graduate of the University of Chicago Pritzker School of Medicine and
subsequently trained at Mayo Clinic and the Weatherall Institute of Molecular Medicine
in Oxford, UK.